GAL-201 / Galimedix Therap - LARVOL DELTA

THE AMYLOID BETA AGGREGATION MODULATOR GAL-201 IS UNDER DEVELOPMENT FOR ORAL AD TREATMENT: COGNITIVE IMPROVEMENT IN A TRANSGENIC AD MODEL (ADPD 2024) - "These amyloid species have been validated by recent positive Phase 3 studies with antibody drugs, such as lecanemab as AD drug target. The available results of the animal study in the Arctic mutation AD model further strengthen the profile of GAL-201 as a promising development candidate for oral Alzheimer therapy. The next step is the initiation of the IND enabling program, before starting a classic Ph 1 SAD/MAD study."

Alzheimer's Disease • CNS Disorders

The Small Molecule GAL-201 Efficiently Detoxifies Soluble Amyloid β Oligomers: New Approach towards Oral Disease-Modifying Treatment of Alzheimer's Disease. (PubMed, Int J Mol Sci) - "Of particular note in this context is the self-propagating detoxification potential of GAL-201, leading to a neutralization of Aβ oligomer toxicity even if GAL-201 has been stepwise removed from the medium (serial dilution), likely due to prion-like conformational changes in Aβ monomer aggregates (trigger effect). The authors conclude that the data presented strongly support the further development of GAL-201 as a novel, orally available AD treatment with potentially superior clinical profile."

Journal • Alzheimer's Disease • CNS Disorders

Preferable phosphate sequestration using polymer-supported Mg/Al layered double hydroxide nanosheets. (PubMed, J Colloid Interface Sci) - "Furthermore, MgAl-201 could be easily regenerated using the NaCO-NaCl binary solution and maintained good reusability without significant capacity loss after 5 adsorption-desorption cycles. The results suggest that MgAl-201 is of great application capability for preferable phosphate sequestration in advanced wastewater treatment."

Journal

Galimedix Accelerating Development of Its Next-Generation Oral Anti-Amyloid Beta Drug GAL-201 for Alzheimer's Disease (Canada Newswire) - "Galimedix...today announced an accelerated program for its promising oral small molecule GAL-201 targeting amyloid beta oligomers, the same target addressed by Biogen's ADUHELM approved earlier this month....The next step on the journey to improve treatment of Alzheimer´s after the injectable ADUHELM will be oral drugs with improved efficacy, safety and convenience. One such drug candidate is our tablet GAL-201. We aim to treat the first patients in a Phase 1/2a clinical trial within 12 months."

New P1/2 trial • Alzheimer's Disease • CNS Disorders

"#InternationalNursesDay 🩺 #IND 🩺 #FlorenceNightingale201 🩺 @ANANursingWorld 🩺 @GeorgiaNurses 🩺 @AANP_NEWS 🩺" (@EricStreetman)

"#InternationalNursesDay 🩺 #IND 🩺 #FlorenceNightingale201 🩺 @ANANursingWorld 🩺 @GeorgiaNurses 🩺 @AANP_NEWS 🩺" (@EricStreetman)

Newly added product (GlobeNewswire) - Preclinical, Alzheimer's Disease

Pipeline update